Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone

Pharmacopsychiatry

Volumn 43, Issue 6, 2010, Pages 216-220

  Kuwilsky, A ^a   Krumm, B ^a   Englisch, S ^a   Dressing, H ^a   Zink, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MENTAL DISEASE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SEROTONIN ANTAGONISTS; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955810627     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0030-1254089     Document Type: Article

References (45)

1. Addington DE, Labelle A, Kulkarni J, etal. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. Can J Psychiatry 2009 54 46-54
2. Addington DE, Pantelis C, Dineen M, etal. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 2004 65 1624-1633
3. Akdede B, Anil Yagcioglu AE, Alptekin K, etal. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J Clin Psychiatry 2006 67 1912-1919
4. Andreasen NC. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry 1989 Suppl 49-58
5. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, etal. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005 66 63-72
6. Assion HJ, Reinbold H, Lemanski S, etal. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008 41 24-28
7. Barbui C, Signoretti A, Mule S, etal. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009 35 458-468
8. Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother 2002 36 839-851
9. Chan J, Sweeting M. Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. J Psychopharmacol 2007 21 657-664
10. Chang JS, Ahn Y-M, Park HJ, etal. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008 69 720-731
11. Correll CU, Rummel-Kluge C, Corves C, etal. Antipsychotic Combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009 35 443-457
12. Dufton BD, Siddique CM. Measures in the day hospital. I. The global assessment of functioning scale. Int J Part Hosp 1992 8 41-49
13. Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Progr Neuro-Psychopharmacol Biol Psychiatry 2008 32 1386-1392
14. Fleischhacker WW, Bergmann KJ, Perovich R, etal. The Hillside akathisia scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol Bull 1989 25 222-226
15. Freudenreich O, Henderson DC, Walsh JP, etal. Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial. Schizophr Res 2007 92 90-94
16. Gharabawi GM, Bossie CA, Mahmoud R, etal. Methodological issues in a comparative study of ziprasidone and risperidone. J Clin Psychiatry 2006 67 162-163
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960 23 56-62
18. Harvey PD, Meltzer H, Simpson GM, etal. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 2004 66 101-113
19. Henderson DC, Fan X, Copeland PM, etal. Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol 2009
20. Honer WG, Thornton AE, Chen EY, etal. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. NE J Med 2006 354 472-482
21. Insel TR, Scolnick EM. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry 2006 11 11-17
22. Josiassen RC, Joseph A, Kohegyi E, etal. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005 162 130-136
23. Kane J, Honigfeld G, Singer J, etal. Clozapine for the treatment-resistant schizophrenic A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988 45 789-796
24. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987 13 261-276
25. Kaye NS. Ziprasidone augmentation of clozapine in 11 patients. J Clin Psychiatry 2003 64 215-216
26. McEvoy JP, Lieberman JA, Stroup TS, etal. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006 163 600-610
27. Munro J, Matthiasson P, Osborne S, etal. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Act Psychiatr Scand 2004 110 292-298
28. National Institute of Mental Health. Chapter 12 CGI. Clinical Global Impression. In: Guy W editor. EDCEU Assessment in Psychopharmacology. Maryland Rockeville 1970 217-222
29. Patil ST, Zhang L, Martenyi F, etal. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Med 2007 13 1102-1107
30. Paton C, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol 2007 27 198-204
31. Schmidt AW, Lebel LA, Howard HR Jr, etal. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001 425 197-201
32. Shiloh R, Zemishlany Z, Aizenberg D, etal. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine A double-blind, placebo-controlled study. Br J Psychiatry 1997 171 569-573
33. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Act Psychiatr Scand 1970 212 Suppl 11-19
34. Stahl SM, Shayegan DK, Stahl SM, etal. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003 64 6-12
35. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic a meta-analysis of randomized, placebo-controlled studies. Act Psychiatr Scand 2009 119 419-425
36. Weiden PJ, Daniel DG, Simpson G, etal. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003 23 595-600
37. Weiden PJ, Simpson GM, Potkin SG, etal. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003 64 580-588
38. Weinberger DR. Schizophrenia drug says goodbye to dopamine. Nature Med 2007 13 1018-1019
39. Ziegenbein M, Calliess IT. Clozapine and ziprasidone: a useful combination in patients with treatment-resistant schizophrenia. J Neuropsychiatry Clin Neurosci 2006 18 246-247
40. Ziegenbein M, Kropp S, Kuenzel HE. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin Neuropharmacol 2005 28 220-224 (Pubitemid 41579619)
41. Ziegenbein M, Wittmann G, Kropp S. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia B A clinical observation. Clin Drug Invest 2006 26 117-124
42. Zink M. Augmentation of olanzapine in treatment-resistant schizophrenia. J Psychiatry Neurosci 2005 30 409-415
43. Zink M, Dressing H. Augmentation of clozapine with atypical antipsychotic substances. Curr Psychiatry Rev 2005 1 165-172
44. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Op Psychiatry 2010 23 103-111
45. Zink M, Kuwilsky A, Krumm B, etal. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: A randomized controlled clinical trial. J Psychopharmacol 2009 23 305-314